PPARA and diabetes mellitus: The above findings indicate that the suppression of PPAR-α/AMPK pathway activity leads to fatty acid metabolic disorders in DCM, and Cirsiliol improves metabolic imbalance by partially restoring the expression of PPAR-α/AMPK and CPT1, providing a basis for targeted modulation of energy metabolism pathways to alleviate diabetic cardiac injury.